- Category: News
- Published on Sunday, 27 May 2012 13:02
- Written by Lara Landis
- Hits: 552
S1 Biophharma recently announced the development of a male-only HSDD drug. The next edition of the DSM-5 makes HSDD a male only condition. A press release put out by the PR Newswire service announced the company’s intention to develop S1P-205. S1P-205 is the first drug to treat the psychological issues for men.
S1P-205 will be combined with Lorexys in most HSDD therapies, according to Nicolas G. Sitchoh, a spokesperson for S1 Biopharma. Researchers are hoping that this drug, combined with Lorexys, will increase the rates of treatment. Unlike Viagra, a drug which works for erectile dysfunction, S1P-205 is intended to provide a holistic approach when used with Lorexys.
The press release defines HSDD as a persistent disorder that causes distress, which marks a change in the earlier marketing for the drug. Asexual activists have attempted to change the definition that appears in the DSM without success.
Cure rates for HSDD are low, and drugs used to treat the condition are only successful when the doctor tries to treat an underlying orientation.